Deuterated Domperidone Formulations for Gastroparesis and Nausea
Summary
The USPTO has published a patent application (US20260083717A1) for deuterated domperidone formulations. These formulations are intended for treating gastroparesis, nausea, vomiting, and other related conditions. The application details specific excipient combinations for these pharmaceutical compositions.
What changed
This document is a published patent application from the USPTO detailing novel pharmaceutical formulations containing deuterated domperidone (d4-domperidone). The application specifies formulations that include combinations of glyceryl stearate, medium chain triglycerides, nonionic poly(ethylene oxide) polymers, and polyethylene glycols. These formulations are intended for treating disorders such as gastroparesis, nausea, vomiting, gastroesophageal reflux disease, and insufficient lactation.
While this is a patent application and not a regulatory rule, it signifies potential future product development in the pharmaceutical sector. Compliance officers in drug manufacturing and healthcare should be aware of emerging therapeutic agents and their compositions. No immediate compliance actions are required, but monitoring patent landscapes can inform R&D and market strategies.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
FORMULATIONS CONTAINING DEUTERATED DOMPERIDONE
Application US20260083717A1 Kind: A1 Mar 26, 2026
Inventors
Piyush PATEL, Catherine PEARCE, Jonathan ISAACSOHN
Abstract
The disclosure provides pharmaceutical formulations comprising d4-domperidone of the formula (I): or a pharmaceutically acceptable salt thereof. The formulations also contain (i) a glyceryl stearate, and a medium chain triglyceride; or (ii) a stearoyl polyoxyl glyceride, a nonionic poly(ethylene oxide) polymer, and a medium chain triglyceride; or (iii) a nonionic poly(ethylene oxide) polymer, and a polyethylene glycol. The disclosure also provides methods for treating a disorder that is gastroparesis, nausea apart from gastroparesis, vomiting apart from gastroparesis, nausea associated with gastroparesis, vomiting associated with gastroparesis, gastroesophageal reflux disease, insufficient lactation, or a combination thereof in a patient, comprising administering to the patient a formulation described herein. In some aspects, the disorder is gastroparesis. In other aspects, the disorder is gastroesophageal reflux disease. In further aspects, the disorder is insufficient lactation.
CPC Classifications
A61K 31/454 A61K 31/085 A61K 47/10 A61K 47/14 A61P 1/08 C07B 59/002 C07B 2200/05
Filing Date
2025-12-03
Application No.
19407389
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.